{"id":40354,"date":"2025-08-29T13:42:26","date_gmt":"2025-08-29T05:42:26","guid":{"rendered":"https:\/\/flcube.com\/?p=40354"},"modified":"2025-08-29T13:42:27","modified_gmt":"2025-08-29T05:42:27","slug":"luye-pharma-reports-1h-2025-revenue-growth-of-3-5-amid-oncology-and-cns-gains","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40354","title":{"rendered":"Luye\u202fPharma Reports 1H\u202f2025 Revenue Growth of 3.5\u202f% Amid Oncology and CNS Gains"},"content":{"rendered":"\n

Luye Pharma Group Ltd. (HKG: 2186<\/a>) on Aug. 28, 2025 released its financial performance for the first half of 2025.<\/p>\n\n\n\n

Consolidated Highlights<\/h3>\n\n\n\n
Metric<\/th>1H\u202f2025<\/th>YoY % Change<\/th><\/tr><\/thead>
Revenue<\/strong><\/td>RMB\u202f3.181\u202fbn<\/strong><\/td>+3.5\u202f%<\/strong><\/td><\/tr>
Oncology<\/strong><\/td>RMB\u202f1.295\u202fbn<\/td>+13.5\u202f%<\/strong><\/td><\/tr>
CNS<\/strong><\/td>RMB\u202f867.5\u202fm<\/td>+5.4\u202f%<\/strong><\/td><\/tr>
Cardiovascular<\/strong><\/td>RMB\u202f693\u202fm<\/td>\u20119.2\u202f%<\/strong><\/td><\/tr>
Metabolism<\/strong><\/td>RMB\u202f180.2\u202fm<\/td>\u20117.9\u202f%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Domestic Portfolio<\/h3>\n\n\n\n

Luye\u2019s competitive product suite covers China\u2019s top five pharmaceutical markets:<\/p>\n\n\n\n

Therapeutic Area<\/th>Key Products<\/th>Market Rank<\/th><\/tr><\/thead>
Oncology<\/strong><\/td>Paclitaxel Liposome, Bevacizumab, Goserelin, Lurbinectedin, Glycididazole, Oxycodone\u202fNaloxone<\/td>1st<\/td><\/tr>
CNS<\/strong><\/td>Quetiapine, Toludesvenlafaxine, Risperidone, Paliperidone, Rotigotine<\/td>2nd<\/td><\/tr>
Cardiovascular<\/strong><\/td>Xuezhikang, Aescinate tablet, Aescinate injection<\/td>4th<\/td><\/tr>
Metabolism<\/strong><\/td>Acarbose, Dulaglutide<\/td>5th<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

International Focus<\/h3>\n\n\n\n

Globally, Luye concentrates on CNS therapeutics, supplying branded and generics such as:<\/p>\n\n\n\n